July 17 (Reuters) - Liminal BioSciences Inc LMNL.TO :
* LIMINAL BIOSCIENCES BROADENS RESEARCH AND DEVELOPMENT PIPELINE WITH NOVEL PRECLINICAL PROGRAM FOR EOSINOPHILIC-DRIVEN DISEASES
* LIMINAL BIOSCIENCES - ACQUIRED ALL OF SHARES IN CAPITAL OF FAIRHAVEN PHARMACEUTICALS
* LIMINAL BIOSCIENCES - WILL PAY C$8 MILLION BY ISSUING SHARES OF CO TO SHAREHOLDERS OF FAIRHAVEN